CClinicalTrials.gg
RecruitingNCT06136702ELEVATE ASUpdated Nov 18, 2023

ELEVATE Acceptability Study

An interventional study of Educational session and Self-sampling in Cervical Cancer, HPV Infection and Acceptability of Health Care, sponsored by University Ghent. Recruiting at 4 sites in 4 countries. Open to female participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by University Ghent · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
1,048
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
Female
01

Study summary

This study includes a community-based, two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will be asked to take a self-sample on-site, followed by a follow-up assessment after 3 months. Attitudes, uptake and users' experiences related to the use of a HPV self-sampling test will be assessed, additionally, the impact on looking for follow up care of self-sampling with standard cervical screening strategies will be assessed and finally the feasibility of an HPV self-sampling in hard-to-reach groups versus educational sessions and standard care will be compared (arm 1 and 2).

Read the detailed description

ELEVATE, a five-year project conducted by an international research alliance led by Ghent University, aims to develop a new test and approach for cervical cancer screening in hard-to-reach populations. The test will combine self-sampling with a new low-cost, portable measurement device and will be validated in dedicated screening trials in Belgium, Brazil, Ecuador, and Portugal. The ELEVATE project targets women in Europe and Latin America who have never been screened or are not regularly screened. These women have a higher risk of developing cervical cancer. The project is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation Action, project number 825747.

To address the gaps in cervical cancer screening, the ELEVATE project is developing a screening strategy to make cervical screening more accessible to hard-to-reach women. This strategy will include the introduction of a new on-site HPV self-sampling screening tool and a portable testing device, able to detect the presence of HPV and cancer biomarker proteins. This portable, low-cost, on-site HPV testing tool will allow to streamline follow-up care for women at risk of developing cervical cancer.

This study is part of the ELEVATE project and takes place in hard-to-reach communities, focusing on socio-economically vulnerable women to assess the acceptability of educational sessions and self-sampling in these communities. This study includes a two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will be asked to take a self-sample on-site, followed by a follow-up assessment after 3 months. Attitudes, uptake and users' experiences related to the use of a HPV self-sampling test will be assessed, additionally, the impact on looking for follow up care of self-sampling with standard cervical screening strategies will be assessed and finally the feasibility of an HPV self-sampling in hard-to-reach groups versus educational sessions and standard care will be compared (arm 1 and 2).

02

Conditions studied

  • Cervical Cancer
  • HPV Infection
  • Acceptability of Health Care

Keywords

  • cervical cancer
  • screening
  • self-sampling
  • HPV
  • acceptability
  • hard-to-reach
  • underscreened
  • community-based
03

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • are between the ages of 25 to 65 years of age, in line with the European Guidelines for initiating and stopping cervical cancer screening
  • (ever been) sexually active;
  • not diagnosed or in treatment for cervical cancer;
  • not having had a hysterectomy
  • not being pregnant
  • Speaking the local language

Exclusion criteria

Exclusion Criteria:

  • younger than 25 years old or older than 65 years old
  • diagnosed or in treatment for cervical cancer
  • having had a hysterectomy
  • being pregnant
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,048 participants (estimated)

Study arms

  • Active comparator
    Educational session and follow-up assessment

    A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake

    Behavioral: Educational session · Behavioral: Follow-up assessment

  • Experimental
    Educational session, self-sampling and follow-up assessment

    A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. In addition, women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site. The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time.

    Behavioral: Educational session · Behavioral: Self-sampling · Behavioral: Follow-up assessment

Interventions

  • BehavioralEducational session

    A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.

  • BehavioralSelf-sampling

    Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.

  • BehavioralFollow-up assessment

    To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.

05

What researchers measure

Primary outcomes

  1. Uptake of cervical cancer screening

    Compare the on-site uptake of self-sampling (arm2) with uptake of standard care (follow-up of arm1)

    Time frame: First encounter (day 0) and 3 months follow-up (day 90)

Secondary outcomes

  1. Attitudes towards HPV self-sampling

    Attitudes towards self-sampling: reasons to accept/decline the self-sample; advantages and disadvantages versus conventional screening.

    Time frame: First encounter (day 0)

  2. User's experiences of HPV self-sampling

    User experiences among those who took a self-sample (easy/difficult; painless/painfull; trustworthy/untrusty; etc.)

    Time frame: First encounter (day 0)

06

Study locations

1 of 4 sites recruiting
  • International centre for reproductive health
    Ghent, East-Flanders 9000, Belgium
    Completed
  • Barretos Cancer Hospital - Fundação Pio XII
    Barretos, Brazil
    • Adhemar Longatto Filho · Contact · longatto@med.uminho.pt
    • Priscila Grecca Pedrão · Sub investigator
    • Anna Karolina da Silva Oliveira · Sub investigator
    • Ricardo dos Reis · Sub investigator
    • Rui Manuel Reis · Sub investigator
    • Adhemar Longatto Filho · Principal investigator
    Not yet recruiting
  • Universidad de Cuenca
    Cuenca, Ecuador
    Completed
  • Escola Nacional de Saúde Pública da Universidade NOVA de Lisboa
    Lisboa, Portugal
    • Sónia Dias · Contact · sonia.dias@ensp.unl.pt · 217512100
    • Sónia Dias · Principal investigator
    • Ana Gama · Sub investigator
    Recruiting
07

References and documents

Study documents

  • Study protocol · Jun 30, 2022
  • Informed consent form · Aug 5, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Icf

08

Registry details

Key details

Study ID
NCT06136702
Lead sponsor
University Ghent
Collaborators
Horizon 2020 - European Commission, Universidade Nova de Lisboa, Universidad de Cuenca, Hospital de Cancer de Barretos - Fundacao Pio XII
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Dec 7, 2022
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Nov 18, 2023

Study contacts

Heleen Vermandere, PhD
Contact
heleen.vermandere@ugent.be
+32-9-332.35.64
Marie Hendrickx, MSC
Contact
marie.hendrickx@ugent.be
+32-9-332.35.64
Bernardo Vega Crespo
principal investigator · Universidad de Cuenca
Adhemar Longatto
principal investigator · Barretos Cancer Hospital
Sónia Dias
principal investigator · Universidade Nova de Lisboa
Olivier Degomme
principal investigator · University Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion